Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been attracting attention for cardiovascular as well as antidiabetic effects since the results of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME Trial) were reported. The hematocrit in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sano, Motoaki, Takei, Makoto, Shiraishi, Yasuyuki, Suzuki, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087622/
https://www.ncbi.nlm.nih.gov/pubmed/27829948
http://dx.doi.org/10.14740/jocmr2760w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087622/
https://www.ncbi.nlm.nih.gov/pubmed/27829948
http://dx.doi.org/10.14740/jocmr2760w

Ejemplares similares